Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly

The post Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly appeared first on 24/7 Wall St..

Eli Lilly (NYSE:LLY) and Johnson & Johnson (NYSE:JNJ) just reported Q1 2026 results that read like two different playbooks for winning in healthcare. Lilly is riding a GLP-1 wave. JNJ is proving that a wide, refreshed portfolio can still compound. Both raised guidance and both are worth putting side by side right now.

GLP-1 Fireworks vs. a Deep Bench

Lilly posted $19.80 billion in revenue, up 55.5% year over year, with Mounjaro alone contributing $8.66 billion and Zepbound adding $4.16 billion. That is a staggering concentration in metabolic drugs, and it delivered non-GAAP EPS of $8.55.

CEO David Ricks said “2026 is off to a strong start”, spotlighting the FDA approval of Foundayo, the first oral GLP-1 pill without food or water restrictions.

JNJ told a very different story. Revenue of $24.062 billion grew 9.9%, split between Innovative Medicine at $15.426 billion and MedTech at $8.636 billion. DARZALEX cleared $3.964 billion, TREMFYA jumped 68.3%, and cardiovascular MedTech rose 13% on Abiomed and Shockwave strength.

CEO Duato called the portfolio “unrivaled”, pointing to ICOTYDE, the first targeted oral peptide for plaque psoriasis.

One Company Concentrates, the Other Diversifies

Lilly is doubling down on metabolic dominance. Ricks highlighted acquisitions of Orna, Centessa, Kelonia, and Ajax, plus a $6 billion Alabama plant and an NVIDIA (NASDAQ:NVDA) drug-discovery lab. Guidance now sits at $82 to $85 billion in revenue and $35.50 to $37 EPS. The trailing P/E of 42 reflects that ambition, and the stock is up 56.86% over the past year.

JNJ is sharpening focus by spinning off DePuy Synthes orthopaedics within 18 to 24 months. Full-year guidance climbed to $100.3 to $101.3 billion with adjusted EPS of $11.45 to $11.65. The dividend rose 3.1% to $1.34, marking 64 consecutive years of increases. Forward P/E of 22 and beta of 0.256 flag it as the calmer name.

What Could Break the Thesis Next

For Lilly, watch how Foundayo ramps against injectable Zepbound and whether the 13% price decline keeps widening as Mounjaro enters China’s NRDL. PineBridge’s 2026 outlook flags lower-cost oral GLP-1 pills as the next expansion catalyst, which fits Lilly’s hand well. Reddit sentiment on LLY swung from a bullish score of 88 in early June to 22 by late June, so retail conviction is jumpy.

For JNJ, the STELARA cliff is real, but TREMFYA’s $1.608 billion quarter shows the handoff is working. Polymarket traders currently give a JNJ Q2 earnings beat only a 49% chance, so the July 15 report is a live wire.

Why I Would Own Both, for Different Reasons

On growth exposure, Lilly screens as the more aggressive name. The GLP-1 category looks like a decade-long story, and Foundayo could pull in patients who never wanted an injection. That said, I do not love paying 33 times forward earnings for a business where two drugs drive the whole engine.

JNJ fits a different job in a portfolio: steadier compounding, a Dividend King record, and a MedTech kicker from VARIPULSE Pro and Shockwave. For readers focused on income and lower volatility, JNJ is the cleaner fit. For those willing to stomach GLP-1 headline risk, Lilly offers the more exciting slope. Owning a slice of each is arguably the easiest way to sleep at night.

The post Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly appeared first on 24/7 Wall St..